GlassScriptPhysician profile
Craig W Carson
NPI 1043288673
$3,764.06
in general payments reported to CMS, 2019-2025
17 companies · $1,898 in 2025
The $1,898 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $33.72 · 2021: $209 · 2022: $499 · 2023: $527 · 2024: $377 · 2025: $1,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367 · Education: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.01 |
| Education | $434.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,269.64 | 2019-2025 | Tavneos, Uplizna, Evenity |
| Astrazeneca Pharmaceuticals LP | $560.09 | 2023-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $345.15 | 2023-2025 | Benlysta |
| Janssen Biotech, INC. | $318.84 | 2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $291.62 | 2025 | |
| Lundbeck LLC | $220.39 | 2021-2022 | |
| Genentech USA, INC. | $187.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $119.84 | 2025 | |
| Janssen Scientific Affairs, LLC | $117.32 | 2022 | |
| Alnylam Pharmaceuticals INC. | $113.00 | 2021 | |
| Ucb, INC. | $98.17 | 2025 | Bimzelx |
| Eisai INC. | $42.74 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $22.05 | 2020 | |
| Organon LLC | $21.81 | 2025 | Hadlima, Renflexis |
| Bioventus LLC | $21.41 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $14.46 | 2025 | Tonmya |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.